Xponance Inc. Cuts Stake in DaVita Inc. (NYSE:DVA)

Xponance Inc. reduced its holdings in shares of DaVita Inc. (NYSE:DVA) by 6.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 10,907 shares of the company’s stock after selling 750 shares during the period. Xponance Inc.’s holdings in DaVita were worth $1,631,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of DVA. Amundi increased its position in shares of DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company’s stock valued at $68,726,000 after purchasing an additional 240,126 shares during the last quarter. FMR LLC increased its position in shares of DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after purchasing an additional 154,061 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its position in shares of DaVita by 256.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock valued at $24,301,000 after purchasing an additional 116,758 shares during the last quarter. Glenmede Trust Co. NA increased its position in shares of DaVita by 731.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after purchasing an additional 108,446 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after purchasing an additional 92,014 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of recent analyst reports. StockNews.com downgraded shares of DaVita from a “buy” rating to a “hold” rating in a research report on Friday. Barclays upped their target price on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. Finally, Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $166.33.

DaVita Stock Down 0.5 %

Shares of NYSE:DVA opened at $148.25 on Friday. The stock has a market cap of $11.86 billion, a P/E ratio of 13.80, a P/E/G ratio of 1.07 and a beta of 0.99. The firm has a fifty day moving average price of $158.53 and a 200 day moving average price of $157.51. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.